Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study
(1) Background: Acute ischemic stroke (AIS) is a possible complication of the coronavirus disease 2019 (COVID-19). Safety and efficacy data on reperfusion therapies (RT)—intravenous thrombolysis and endovascular treatment (EVT)—in stroke patients with COVID-19 is lacking. (2) Methods: We performed a...
Main Authors: | Justina Jurkevičienė, Mantas Vaišvilas, Rytis Masiliūnas, Vaidas Matijošaitis, Antanas Vaitkus, Dovilė Geštautaitė, Saulius Taroza, Paulius Puzinas, Erika Galvanauskaitė, Dalius Jatužis, Aleksandras Vilionskis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/11/3004 |
Similar Items
-
Efficacy and safety of intravenous thrombolysis for acute ischemic stroke within 3–4.5 hours in Lithuania
by: Aleksandras VILIONSKIS, et al.
Published: (2012-03-01) -
High Prevalence of Atrial Fibrillation in a Lithuanian Stroke Patient Cohort
by: Rytis Masiliūnas, et al.
Published: (2022-06-01) -
Posterior Circulation Stroke Patients Receive Less Reperfusion Therapy Because of Late Arrival and Relative Contraindications: A Retrospective Study
by: Aleksandra Ekkert, et al.
Published: (2023-08-01) -
Intravenous r-tPA Dose Influence on Outcome after Middle Cerebral Artery Ischemic Stroke Treatment by Mechanical Thrombectomy
by: Marius Kurminas, et al.
Published: (2020-07-01) -
Acute Reperfusion Therapies for Acute Ischemic Stroke
by: Rajeel Imran, et al.
Published: (2021-08-01)